 Michelle Barron
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 6 | 2024 | 533 | 0.950 |
Why?
| | Hospitalization | 18 | 2025 | 2075 | 0.740 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1033 | 0.720 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 309 | 0.700 |
Why?
| | Influenza, Human | 6 | 2024 | 602 | 0.640 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 35 | 0.580 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2016 | 146 | 0.570 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 68 | 0.510 |
Why?
| | Vaccines, Attenuated | 1 | 2016 | 125 | 0.500 |
Why?
| | Viremia | 2 | 2009 | 131 | 0.500 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 32 | 0.460 |
Why?
| | Staphylococcal Infections | 6 | 2020 | 391 | 0.420 |
Why?
| | Antifungal Agents | 9 | 2020 | 130 | 0.410 |
Why?
| | Adult | 37 | 2025 | 35607 | 0.410 |
Why?
| | Ambulatory Care | 5 | 2022 | 506 | 0.390 |
Why?
| | Antibodies, Viral | 1 | 2016 | 602 | 0.390 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2009 | 576 | 0.380 |
Why?
| | Dendritic Cells | 2 | 2006 | 481 | 0.360 |
Why?
| | Middle Aged | 30 | 2025 | 31165 | 0.350 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 436 | 0.340 |
Why?
| | Bacteremia | 3 | 2020 | 194 | 0.330 |
Why?
| | Serotonin Syndrome | 1 | 2010 | 5 | 0.330 |
Why?
| | Oxazolidinones | 1 | 2010 | 15 | 0.330 |
Why?
| | Acetamides | 1 | 2010 | 36 | 0.320 |
Why?
| | Methicillin | 1 | 2009 | 11 | 0.310 |
Why?
| | Aged | 24 | 2025 | 22101 | 0.300 |
Why?
| | Adaptive Immunity | 1 | 2009 | 161 | 0.300 |
Why?
| | HIV-1 | 2 | 2006 | 838 | 0.300 |
Why?
| | Emergency Service, Hospital | 9 | 2025 | 1917 | 0.290 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2020 | 221 | 0.290 |
Why?
| | Platelet Transfusion | 1 | 2009 | 61 | 0.290 |
Why?
| | Humans | 56 | 2025 | 129687 | 0.290 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 189 | 0.290 |
Why?
| | Immunization, Secondary | 3 | 2022 | 87 | 0.280 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 248 | 0.270 |
Why?
| | Immunocompromised Host | 4 | 2024 | 199 | 0.270 |
Why?
| | Vitamin K Deficiency | 1 | 2006 | 8 | 0.250 |
Why?
| | AIDS Vaccines | 1 | 2006 | 47 | 0.250 |
Why?
| | Male | 30 | 2025 | 63691 | 0.240 |
Why?
| | Rhizopus | 1 | 2005 | 5 | 0.240 |
Why?
| | Blood Platelets | 1 | 2009 | 386 | 0.240 |
Why?
| | Facial Pain | 1 | 2005 | 13 | 0.240 |
Why?
| | Female | 31 | 2025 | 68751 | 0.240 |
Why?
| | Mucormycosis | 1 | 2005 | 22 | 0.240 |
Why?
| | Cross Infection | 3 | 2014 | 217 | 0.240 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.230 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 277 | 0.230 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 34 | 0.220 |
Why?
| | Carbapenems | 2 | 2014 | 23 | 0.220 |
Why?
| | Klebsiella Infections | 2 | 2014 | 25 | 0.220 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.220 |
Why?
| | Klebsiella pneumoniae | 2 | 2014 | 42 | 0.220 |
Why?
| | beta-Lactamases | 2 | 2014 | 41 | 0.220 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 402 | 0.220 |
Why?
| | Immunity, Innate | 1 | 2009 | 804 | 0.220 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2024 | 135 | 0.210 |
Why?
| | Mycoses | 1 | 2003 | 73 | 0.210 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 120 | 0.210 |
Why?
| | Candidiasis, Invasive | 2 | 2014 | 6 | 0.200 |
Why?
| | United States | 14 | 2025 | 13906 | 0.200 |
Why?
| | Aged, 80 and over | 10 | 2025 | 7064 | 0.200 |
Why?
| | Sinusitis | 1 | 2005 | 211 | 0.200 |
Why?
| | Brain Diseases | 1 | 2003 | 134 | 0.200 |
Why?
| | Sputum | 1 | 2024 | 302 | 0.190 |
Why?
| | Viral Vaccines | 1 | 2023 | 95 | 0.190 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 530 | 0.190 |
Why?
| | Adolescent | 15 | 2025 | 20415 | 0.190 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 228 | 0.180 |
Why?
| | Tuberculosis | 1 | 2024 | 273 | 0.180 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.170 |
Why?
| | Lung Transplantation | 2 | 2013 | 290 | 0.170 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 19 | 0.170 |
Why?
| | Case-Control Studies | 7 | 2023 | 3381 | 0.170 |
Why?
| | Cryptococcosis | 1 | 2020 | 26 | 0.170 |
Why?
| | Intensive Care Units | 5 | 2021 | 737 | 0.160 |
Why?
| | Zygomycosis | 2 | 2009 | 6 | 0.160 |
Why?
| | Organ Transplantation | 3 | 2020 | 228 | 0.160 |
Why?
| | Retrospective Studies | 9 | 2024 | 14525 | 0.160 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.150 |
Why?
| | RNA, Messenger | 5 | 2024 | 2702 | 0.150 |
Why?
| | Cefazolin | 1 | 2018 | 18 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 367 | 0.150 |
Why?
| | Pneumonia | 1 | 2024 | 619 | 0.150 |
Why?
| | Vaccination | 5 | 2024 | 1348 | 0.140 |
Why?
| | Young Adult | 11 | 2025 | 12457 | 0.140 |
Why?
| | Disease Outbreaks | 3 | 2015 | 349 | 0.130 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2016 | 38 | 0.130 |
Why?
| | Echinocandins | 2 | 2014 | 7 | 0.130 |
Why?
| | North America | 1 | 2016 | 292 | 0.120 |
Why?
| | Anti-Bacterial Agents | 4 | 2020 | 1708 | 0.120 |
Why?
| | Spores, Bacterial | 1 | 2015 | 18 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1035 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 27 | 0.120 |
Why?
| | Containment of Biohazards | 1 | 2015 | 12 | 0.120 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 20 | 0.120 |
Why?
| | Population Surveillance | 2 | 2015 | 439 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 131 | 0.110 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 87 | 0.110 |
Why?
| | Treatment Outcome | 9 | 2020 | 10221 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 3 | 2020 | 349 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 265 | 0.110 |
Why?
| | Bacterial Infections | 1 | 2016 | 233 | 0.110 |
Why?
| | Heart Transplantation | 1 | 2020 | 722 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 219 | 0.110 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 3 | 0.110 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 210 | 0.110 |
Why?
| | Critical Care | 2 | 2016 | 551 | 0.100 |
Why?
| | Vaccines, Combined | 2 | 2023 | 48 | 0.100 |
Why?
| | Invasive Pulmonary Aspergillosis | 1 | 2013 | 6 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 31 | 0.100 |
Why?
| | Daptomycin | 1 | 2013 | 19 | 0.100 |
Why?
| | Creatine Kinase | 1 | 2013 | 75 | 0.100 |
Why?
| | Risk Factors | 8 | 2024 | 9787 | 0.100 |
Why?
| | Rectum | 1 | 2014 | 170 | 0.100 |
Why?
| | Global Health | 1 | 2015 | 328 | 0.100 |
Why?
| | Drug Interactions | 2 | 2013 | 397 | 0.100 |
Why?
| | Muscular Diseases | 1 | 2013 | 108 | 0.100 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.090 |
Why?
| | Chemoprevention | 1 | 2011 | 91 | 0.090 |
Why?
| | Linezolid | 1 | 2010 | 20 | 0.080 |
Why?
| | Sertraline | 1 | 2010 | 30 | 0.080 |
Why?
| | Citalopram | 1 | 2010 | 30 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 598 | 0.080 |
Why?
| | Child, Preschool | 5 | 2023 | 10487 | 0.080 |
Why?
| | Lung Diseases, Fungal | 1 | 2009 | 13 | 0.080 |
Why?
| | Tremor | 1 | 2010 | 60 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2023 | 851 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 430 | 0.070 |
Why?
| | Child | 6 | 2023 | 20882 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 789 | 0.070 |
Why?
| | Sequence Analysis, DNA | 2 | 2024 | 778 | 0.070 |
Why?
| | Newspapers as Topic | 1 | 2006 | 10 | 0.070 |
Why?
| | Professional Misconduct | 1 | 2006 | 11 | 0.070 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 426 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 50 | 0.060 |
Why?
| | Ethics, Research | 1 | 2006 | 31 | 0.060 |
Why?
| | Hemorrhagic Disorders | 1 | 2006 | 8 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 26 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2006 | 1937 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 36 | 0.060 |
Why?
| | Drug Antagonism | 1 | 2006 | 10 | 0.060 |
Why?
| | Phenytoin | 1 | 2006 | 20 | 0.060 |
Why?
| | Prothrombin Time | 1 | 2006 | 33 | 0.060 |
Why?
| | Vitamin K | 1 | 2006 | 41 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 124 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 30 | 0.060 |
Why?
| | Thrombolytic Therapy | 1 | 2006 | 137 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 190 | 0.060 |
Why?
| | Tissue Plasminogen Activator | 1 | 2006 | 222 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 5 | 0.060 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2024 | 69 | 0.050 |
Why?
| | Liposomes | 1 | 2005 | 171 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2006 | 208 | 0.050 |
Why?
| | Pain | 1 | 2010 | 786 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2006 | 262 | 0.050 |
Why?
| | Autopsy | 1 | 2003 | 92 | 0.050 |
Why?
| | Antiviral Agents | 2 | 2022 | 718 | 0.050 |
Why?
| | Time Factors | 4 | 2022 | 6545 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 133 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 7145 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 299 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 57 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2006 | 321 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 83 | 0.050 |
Why?
| | Advisory Committees | 1 | 2024 | 216 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 79 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 88 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2006 | 1110 | 0.050 |
Why?
| | Infant | 3 | 2016 | 8987 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2002 | 223 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2002 | 310 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 1270 | 0.050 |
Why?
| | Lipopeptides | 2 | 2014 | 13 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 267 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 18 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 477 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 197 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 487 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2015 | 1875 | 0.040 |
Why?
| | Hospitals | 2 | 2015 | 646 | 0.040 |
Why?
| | Vancomycin | 1 | 2020 | 78 | 0.040 |
Why?
| | RNA, Viral | 1 | 2002 | 620 | 0.040 |
Why?
| | Prevalence | 1 | 2006 | 2563 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2018 | 13 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2378 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4102 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2644 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 2022 | 0.040 |
Why?
| | Endocarditis | 1 | 2018 | 38 | 0.040 |
Why?
| | Echocardiography | 1 | 2020 | 635 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 668 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2002 | 2724 | 0.030 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2015 | 26 | 0.030 |
Why?
| | Developed Countries | 1 | 2015 | 33 | 0.030 |
Why?
| | Patient Isolation | 1 | 2015 | 16 | 0.030 |
Why?
| | Contraindications | 1 | 2015 | 90 | 0.030 |
Why?
| | Ebolavirus | 1 | 2015 | 34 | 0.030 |
Why?
| | Africa | 1 | 2015 | 99 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 63 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2015 | 57 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 372 | 0.030 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2015 | 42 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 5759 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 85 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 181 | 0.030 |
Why?
| | Travel | 1 | 2015 | 122 | 0.030 |
Why?
| | Colorado | 2 | 2014 | 4405 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 114 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 317 | 0.030 |
Why?
| | Fluorobenzenes | 1 | 2013 | 15 | 0.030 |
Why?
| | Rosuvastatin Calcium | 1 | 2013 | 20 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2014 | 175 | 0.030 |
Why?
| | Allografts | 1 | 2013 | 137 | 0.030 |
Why?
| | Simvastatin | 1 | 2013 | 60 | 0.020 |
Why?
| | Dystrophin | 1 | 1992 | 34 | 0.020 |
Why?
| | Muscular Dystrophies | 1 | 1992 | 35 | 0.020 |
Why?
| | Feces | 1 | 2015 | 442 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1012 | 0.020 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2014 | 205 | 0.020 |
Why?
| | Neoplasms | 1 | 2006 | 2454 | 0.020 |
Why?
| | APACHE | 1 | 2011 | 65 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1433 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1551 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 614 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1500 | 0.020 |
Why?
| | Anticoagulants | 1 | 2015 | 637 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1988 | 0.020 |
Why?
| | Risk | 1 | 2013 | 855 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6412 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 601 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 458 | 0.020 |
Why?
| | Sulfonamides | 1 | 2013 | 497 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 63 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2009 | 2470 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2015 | 900 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 323 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1506 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 160 | 0.020 |
Why?
| | Mass Screening | 1 | 2015 | 1192 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 63 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2006 | 20 | 0.020 |
Why?
| | Echo-Planar Imaging | 1 | 2006 | 18 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 41 | 0.020 |
Why?
| | Convalescence | 1 | 2006 | 18 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1005 | 0.020 |
Why?
| | Drug Approval | 1 | 2006 | 87 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2006 | 326 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 287 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 256 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 858 | 0.010 |
Why?
| | Risk Assessment | 1 | 2013 | 3260 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 836 | 0.010 |
Why?
| | Research | 1 | 2006 | 420 | 0.010 |
Why?
| | Patient Selection | 1 | 2006 | 660 | 0.010 |
Why?
| | Lung | 1 | 2013 | 3937 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5434 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2006 | 2739 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2006 | 4892 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 3969 | 0.010 |
Why?
| | Brain | 1 | 2006 | 2677 | 0.010 |
Why?
| | DNA Probes | 1 | 1992 | 60 | 0.010 |
Why?
| | X Chromosome | 1 | 1992 | 50 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1992 | 43 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1992 | 103 | 0.010 |
Why?
| | Sex Chromosome Aberrations | 1 | 1992 | 62 | 0.010 |
Why?
| | Muscles | 1 | 1992 | 320 | 0.010 |
Why?
| | Exons | 1 | 1992 | 341 | 0.010 |
Why?
| | Blotting, Western | 1 | 1992 | 1204 | 0.010 |
Why?
| | Biopsy | 1 | 1992 | 1087 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1368 | 0.000 |
Why?
|
|
Barron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|